- Home
- GECC vs FBIO Comparison
GECC vs FBIO Comparison
Compare GECC & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GECC | FBIO |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.8M | 113.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GECC | FBIO |
|---|---|---|
| Price | $7.03 | $3.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $10.75 | ★ $16.50 |
| AVG Volume (30 Days) | 122.6K | ★ 560.7K |
| Earning Date | 11-04-2025 | 11-14-2025 |
| Dividend Yield | ★ 21.72% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $46,553,000.00 | ★ $62,303,000.00 |
| Revenue This Year | $32.16 | $29.71 |
| Revenue Next Year | $3.26 | $49.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.68 | N/A |
| 52 Week Low | $6.61 | $1.33 |
| 52 Week High | $11.46 | $4.20 |
Technical Indicators
Market Signals| Indicator | GECC | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | 43.91 | 67.40 |
| Support Level | $6.61 | $3.54 |
| Resistance Level | $6.94 | $3.81 |
| Average True Range (ATR) | 0.27 | 0.22 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 31.31 | 82.32 |
Price Performance
Historical ComparisonAbout GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.